Press Releases

In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS --(BUSINESS WIRE)--Aug. 9, 2022-- Regulatory News : Nanobiotix (Paris:NANO) (NASDAQ:NBTX): Market: Euronext

PARIS & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 13, 2022-- Regulatory News : NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today issued the

In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS --(BUSINESS WIRE)--Jul. 8, 2022-- Regulatory News : Nanobiotix (Paris:NANO)(NASDAQ:NBTX) Market: Euronext Paris

In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulations of the Autorité des Marchés Financiers ( French Financial Markets Authority ) PARIS --(BUSINESS WIRE)--Jun. 9, 2022-- Regulatory News : Nanobiotix (Paris:NANO) (NASDAQ:NBTX): Market: Euronext

Data reported at the 2022 Annual Meeting of the American Society for Clinical Oncology NBTXR3 is being developed as a product candidate with potential to integrate across the standards of care in oncology, and these data from collaborator-sponsored phase 1b/2 studies add support for the

PARIS & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 2, 2022-- Regulatory News : NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘ Company ’’) , a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced

On-track to activate first US clinical trial sites in on-going pivotal phase III global registration study, NANORAY-312, in locally advanced head and neck squamous cell carcinoma (LA-HNSCC) in Q3 2022 Received preliminary feedback from FDA informing development of pivotal Phase III protocol for

PARIS & CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 17, 2022-- Regulatory News : NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced

PARIS & CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 11, 2022-- Regulatory News : NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the " Company "), a clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that

PARIS & CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 4, 2022-- Regulatory News : NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘ Company ’’) , a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced